Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stockwatch: Bad debts and outcomes

This article was originally published in Scrip

Executive Summary

Despite what a young biotechnology company's bankers will tell them, raising debt ahead of the approval and commercialisation of the company's first product, is rarely a good idea. The rationale, which probably sounds good at the time, goes something like this. Once the revenues start flowing from the soon to be approved product, they will easily cover the interest on the debt and by the time the principal, or the convertible become due, the company will be cash flow positive and would be able to pay-off, refinance or convert the liability into shares.

You may also be interested in...



Stock Watch: AstraZeneca’s Third-Quarter Crescendo

In a third-quarter earnings report that was difficult to fault AstraZeneca left big pharma earnings season on a high note. But raised full-year guidance depends on Evusheld sales and maybe China.

Stock Watch: The Pandemic Still Permeates Through Q3 Earnings

While big tech is suffering from a return to normality after the pandemic, big pharma always had a recovery in its base business to return to. But after the third-quarter earnings season, it seems both base and pandemic pharmaceutical businesses are still co-existing for now.

Stock Watch: Merck And Pfizer Reclaim Pharmaceutical Defensiveness

Merck grew sales, increased financial guidance and beat analysts’ expectations, noting a base business recovery from the pandemic. Pfizer increased guidance and beat expectations for different reasons.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC017272

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel